Johnson & Johnson Archives -

Jury trial levies $750m damages on J&J over talc and cancer

https://pharmaphorum.com/news/jury-trial-levies-750m-damages-on-jj-over-talc-and-cancer/

NICE rejects J&J’s Spravato for treatment-resistant depression

https://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/

Washington State is latest to sue Janssen over opioid marketing

https://pharmaphorum.com/news/washington-state-is-latest-to-sue-jj-over-opioid-marketing/

FDA knocks back ViiV, J&J’s long-acting HIV regimen

https://pharmaphorum.com/news/fda-knocks-back-viiv-jjs-long-acting-hiv-regimen/

J&J to buy US biotech Taris and its bladder cancer drug device

https://pharmaphorum.com/news/jj-to-buy-us-biotech-taris-and-its-bladder-cancer-drug-device/

BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM

https://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

https://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

https://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/

13th Annual Pharma Resource Planning and Portfolio Management

https://pharmaphorum.com/events/13th-annual-pharma-resource-planning-and-portfolio-management/

Search